

No.: 02/CV-AGP

An Giang, February 13, 2025

Regarding the explanation of profit after tax in the  
2024 financial statements, which fluctuated by more  
than 10% compared to the same period last year

**To: - State Securities Commission  
- Hanoi Stock Exchange**

**1. Organization name: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

- Exchange: **UPCOM** - Securities symbol:

- Address: 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province,

- Contact phone: 02963.856.960

Fax: 02963.957.434

Type of disclosed information:  24 hours  72 hours  as required  extraordinary  periodic

**2. Disclosure information content:** Explanation of the fluctuation in profit after tax in the 2024 income statement, which has fluctuated by more than 10% compared to 2023.

| Items                               | Code | Year 2024       | Year 2023       | Change         | Ratio    |
|-------------------------------------|------|-----------------|-----------------|----------------|----------|
| Net sales                           | 10   | 793,261,193,442 | 725,130,106,273 | 68,131,087,169 | 9.40%    |
| Cost of sales                       | 11   | 560,244,231,092 | 510,403,984,936 | 49,840,246,156 | 9.76%    |
| Gross profit                        | 20   | 233,016,962,350 | 214,726,121,337 | 18,290,841,013 | 8.52%    |
| Financial income                    | 21   | 2,974,573,855   | 630,869,494     | 2,343,704,361  | 371.50%  |
| Financial expenses                  | 22   | 32,597,535,588  | 39,089,942,209  | -6,492,406,621 | -16.61%  |
| Selling expenses                    | 25   | 97,704,189,406  | 82,644,842,348  | 15,059,347,058 | 18.22%   |
| General and administration expenses | 26   | 45,094,611,404  | 39,692,723,111  | 5,401,888,293  | 13.61%   |
| Net operating profit                | 30   | 60,595,199,807  | 53,929,483,163  | 6,665,716,644  | 12.36%   |
| Other profit                        | 40   | -114,016,309    | 266,270,942     | -380,287,251   | -142.82% |
| Total accounting profit before tax  | 50   | 60,481,183,498  | 54,195,754,105  | 6,285,429,393  | 11.60%   |
| Profit after tax                    | 60   | 48,889,738,710  | 43,612,786,683  | 5,276,952,027  | 12.10%   |

2024 continues to be a volatile year for the global economy. The Vietnamese pharmaceutical industry faced numerous challenges and difficulties, including rising production costs due to supply chain disruptions and exchange rate pressures.

However, Agimexpharm has strengthened cost control, particularly interest expenses. Additionally, thanks to a product strategy aligned with industry development trends, Agimexpharm's business performance in 2024 achieved positive results: revenue increased by 9.4% and profit after tax increased by 12.1% compared to 2023.

Sincerely.


**Recipients:**

- As stated above;
- Archived: Secretary of the BoDs

**Organization representative**

*Legal representative*

**GENERAL DIRECTOR**



**PHAR. NGUYEN VAN KHA**